

Maria Gisella Cavallo Curriculum Vitae

Rome 16.11.2019

Part I – General Information

Full Name	Maria Gisella Cavallo
Spoken Languages	Italian English French

Part II – Education

Type	Year	Institution	Notes
University graduation	1986	Sapienza University of Rome	Degree in Medicine and Surgery <i>cum laude</i>
Post-graduate studies			
PhD	1991	Sapienza University of Rome	PhD in Endocrinology and Metabolism
Specialty	1989	Sapienza University of Rome	Degree in Endocrinology <i>cum laude</i>
Specialty	1998	Sapienza University of Rome	Degree in Oncology <i>cum laude</i>
Licensure	1986	Ordine dei Medici di Roma	Registration n.38541

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
2000	present	Sapienza University of Rome	<i>Assistant Professor of Internal Medicine (Ricercatore a tempo indeterminato)</i>
1997	2000	University Campus Biomedico Facoltà di Medicina e Chirurgia	<i>Adjunct professor of “Patologia Medica Integrata”</i>
1993	1995	Sapienza University of Rome Istituto II Clinica Medica	<i>Postdoctoral Research Fellow and clinical assistant</i>

1991	1992	Department of Diabetes and Immunogenetics, St. Bartholomew's Hospital, London, UK.	<i>Visiting scientist</i>
1988	1991	Division of Immunobiology, National Institute for Biological Standards and Control, London, UK	<i>Research Fellow</i>
1987	1987	Department of Immunology, United Medical and Dental Schools of Guy's and St. Thomas's Hospitals, University of London	<i>Visiting Research Fellow</i>
National Scientific Qualification for academic positions			
2013	2020	Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR)	<i>National Scientific Qualification for Associate Professor for the SC 06/D2, SSD MED/13, Endocrinology</i>
2017	2023	Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR)	<i>National Scientific Qualification for Associate Professor for the SC 06/B1, SSD MED/09, Endocrinology</i>
2018	2024	Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR)	<i>National Scientific Qualification for full Professor for the SC 06/D2, SSD MED/13, Endocrinology</i>
2018	2024	Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR)	<i>National Scientific Qualification for full Professor for the SC 06/B1, SSD MED/09, Internal Medicine</i>

IIIB – Clinical Appointments

Start	End	Institution	Position
2000	present	Azienda Policlinico Umberto I	<i>Dirigente Medico UOC Medicina Interna DAI Medicina interna e specialità mediche</i>

IIIC – Other Appointments

2018-	Diabetes Metabolism Research/Reviews	<i>Member of Editorial Board</i>
2014-2019	Società Italiana di Diabetologia	<i>Member of Editorial Committee</i>
2013-2015	Sapienza University Rome, Italy	<i>Member of the research Committee</i>
1996	Department of Autoimmunity, Bristol Mayers Squibb Pharmaceutical Research Institute, Seattle	<i>Visiting scientist</i>

Part IV – Teaching experience

Year	Institution	Lecture/Course
1997-2001	University Campus Biomedico, Rome, Italy	<i>Docente nel corso di Patologia Medica Integrata, facoltà di Medicina e Chirurgia</i>

2000 - 2003	Sapienza University Rome, Italy	<i>Docente nel corso di Perfezionamento in "Prevenzione e Terapia dell'Obesità"</i>
2001-	Sapienza University Rome, Italy	<i>Docente del corso integrato "Metodologia VI" per il corso di Laurea Specialistica in Medicina e chirurgia, III anno</i>
2001-2008	Sapienza University Rome, Italy	<i>Docente Scuola di Specializzazione in Gastroenterologia III</i>
2005-	Sapienza University Rome, Italy	<i>Membro del Collegio dei Docenti Corso di Specializzazione in Medicina Termale</i>
2012-	Sapienza University Rome, Italy	<i>Membro del Collegio dei Docenti Corso di Specializzazione in Medicina Interna</i>
2016-	Sapienza University Rome, Italy	<i>Docente del corso integrato "Medicina Interna III", VI anno II semestre, CLMC</i>
2017-	Sapienza University Rome, Italy	<i>Membro del Collegio dei Docenti del Dottorato di Ricerca in Scienze Endocrinologiche</i>
2018-	Sapienza University Rome, Italy	<i>Membro del Collegio dei Docenti Corso di Specializzazione in Endocrinologia e Malattie del Metabolismo</i>

Part V - Society memberships, Awards and Honors

Year	Institution	Title
1986-	Italian Society of Diabetology (SID)	<i>Member</i>
1986-1990	European Association for the Study of Diabetes (EASD)	<i>Member</i>
1986-1992	Italian Society of Endocrinology (SIE)	<i>Member</i>
1989-1991	Sapienza University "Istituto Pasteur-Fondazione Cenci Bolognetti"	<i>Research Fellowship</i>
1990	Italian Society of Diabetology (SID)	<i>Meeting award</i>
1990	European Association for the Study of Diabetes (EASD)	<i>EASD meeting Copenhagen 1990 Travel grant</i>
1990	Parma Diabete Università di Parma	<i>Joung Investigator award</i>
1991	Consiglio Nazionale delle Ricerche (CNR)	<i>Borsa di Studio per l'estero</i>
1992	Italian Society of Diabetology (SID)	<i>Borsa di studio per lo svolgimento di attività di ricerca presso centri esteri</i>
1994-2000	Immunology of Diabetes Society (IDS)	<i>Member</i>
1993-1995	Juvenile Diabetes Research Foundation International (JDRF)	<i>Award Fellowship</i>

2005-2017	Socio della Società Italiana di Medicina Interna (SIMI)	<i>Member</i>
2005-2017	Collegio dei docenti Universitari in Medicina Interna 09” (COLMED 09)	<i>Member</i>

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Role	Grant value
2005	Analisi di geni candidati per il difetto di secrezione insulinica e di insulino resistenza negli stati di alterata regolazione del glucosio e nel diabete	Sapienza University Ricerche di FACOLTÀ	PI	1520
2005	Studio della variabilità di fattori endocrino-metabolici di cescita tessutale in campioni omogenei di atleti in condizioni basali e di allenamento.	Italian Ministry of Health 2005 “Programma di ricerca sui farmaci, sulle sostanze e sulle pratiche mediche utilizzabili a fini di doping nelle attività sportive”	Responsabile di Unità Operativa	30000
2006	Analisi di geni candidati per il difetto di secrezione insulinica e di insulino resistenza negli stati di alterata regolazione del glucosio e nel diabete	Sapienza University Ricerche di FACOLTÀ	PI	1540
2007	Ricerca di determinanti genetici di diabete tipo 2 ad insorgenza precoce [early-onset type 2 diabetes (EOD)], tramite analisi di geni candidati	Sapienza University Ricerche di FACOLTÀ	PI	1400
2008	Ricerca di determinanti genetici di diabete tipo 2 ad insorgenza precoce [early-onset type 2 diabetes (EOD)], tramite analisi di geni candidati (II)	Sapienza University Ricerche di FACOLTÀ	PI	1500
2008	La regolazione dell’accumulo e della distribuzione del grasso corporeo: aspetti patogenetici, nutrizionali e terapeutici in relazione al rischio cardiometabolico	Italian Ministry of Education, Universities and Research Research Projects of National Interest (PRIN) 2008	Responsabile di Unità Operativa	24000

2009	Ruolo della ipovitaminosi D nella patogenesi e nell'evoluzione della sindrome metabolica, del diabete mellito di tipo 2 e della steatosi epatica non alcol correlata (NAFLD)	Sapienza University Ricerche di ATENEO FEDERATO 2009	PI	5000
2011	Efficacia della supplementazione orale con vit. D3 nel ridurre la steato-infiammazione epatica e nel modificare il profilo di rischio cardio-metabolico in adulti diabetici affetti da steatosi/steatoepatite non alcool-correlata (NAFLD/NASH)	Sapienza University Ricerche UNIVERSITARIE 2011	PI	5000
2015	The "Sapienza University Mortality and Morbidity Event Rate (SUMMER) study in diabetes"	Finanziamento Fondazione Banca D'Italia	PI	25000
2016	Clinical, histological, immunological and genetic determinants of adipose tissue associated immune responses and liver inflammation in obese patients candidate to bariatric surgery	Sapienza University Ricerche UNIVERSITARIE 2016	PI	33600
2016	A randomized, double blind placebo controlled clinical trial to assess the efficacy and safety of sitagliptin on bone measures in women affected by type 2 diabetes. A gender-oriented approach to address a gender-specific frailty. The SLOWDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) study"	AIFA Finanziamento per la Ricerca Indipendente 2016: Responsabile Scientifico	PI	495000
2017	Interazione tra Dipeptidil Peptidasi-4 e Vitamina D nell'asse osso-tessuto adiposo in soggetti con diabete di tipo 2	Finanziamento Fondazione Banca D'Italia	PI	64000
2018	DPP-4 activity in inflammation and bone metabolism: role of the DPP-4 in Vitamin D balance and bone health in relation to glucose metabolism and other metabolic complications of obesity	Sapienza University Ricerche UNIVERSITARIE 2018	PI	10000

Via – Participation to International Clinical Trials

Year	Position	Title
2007 2011	Principal Investigator	International, Randomised Clinical Trial - Andromeda 901: double-blind Diapep 277 vs placebo in type 1 diabetes at diagnosis
2008 2011	Principal Investigator	International, Multicenter, Randomised Clinical Trial DEFEND-1: a Phase 3 Trial with Otelixizumab (a humanized anti-CD3 MAb) in type 1 diabetes
2010 2012	Principal Investigator	International, Multicenter, Randomised Clinical Trial DEFEND-2: a Phase 3 Trial with Otelixizumab (a humanized anti-CD3 MAb) in type 1 diabetes
2011 2014	Principal Investigator	International, Multicenter, Randomised Clinical Trial Andromeda 1001: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Investigate The Clinical Efficacy And Safety Of Diapep277® In Newly Diagnosed Type 1 Diabetes Subjects
2016 2018	Principal Investigator	International, Multicenter, Prospective Study REFLECT: Studio prospettico, non interventistico, multicentrico per la valutazione della sicurezza e dell'efficacia di insulina degludec in una popolazione di pazienti con diabete mellito tipo 1 e 2 nella reale pratica clinica.
2017 2019	Principal Investigator	International, Multicenter Randomised Clinical Trial PRONTO-T1D (I8B-MC-ITRM) - A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes"
2018 2019	Principal Investigator	International, Multicenter, Clinical Trial SAGE: Multinational, cross-sectional, observational study to describe glycemic control and quality of life for type 1 diabetic adult patients.
2018	Principal Investigator	International, Multicenter, Clinical Trial INSAX - In-market utilisation of liraglutide used for weight management in Europe: a retrospective medical record review study
2019	Principal Investigator	International, Multicenter, Clinical Trial EU-CAPTURE - A non-interventional cross-sectional study to capture the prevalence of cardiovascular disease in patients with type 2 diabetes in selected countries in Europe
2019	Principal Investigator	International, Multicenter, Randomised Clinical Trial FLOW -Effetti di semaglutide rispetto al placebo sulla progressione dell'insufficienza Renale in soggetti con diabete di tipo 2 e malattia renale cronica

Part VII – Research Activities

Keywords	Brief Description
NAFLD Adipose tissue Inflammation	Pathophysiological aspects of body fat regulation in subjects with type 2 diabetes and metabolic syndrome. Mechanisms linking NAFLD to systemic inflammation and adipose tissue dysfunction
Vitamin D deficiency VD/VDR axis	Study of the association between vitamin D status and metabolic diseases. Variation in genes regulating vitamin D metabolism. Effects of vitamin D supplementation on metabolic variables.
Type 2 diabetes Glucose regulation Metabolic syndrome	Study of the phenotypical heterogeneity of patients with type 2 diabetes. Genetics of type 2 diabetes and impaired glucose regulation. Identification of new biomarkers of diabetes progression and development of cardiovascular complications.
Type 1 diabetes Immunity Immunotherapy	Study of the etiopathogenesis of type 1 diabetes including alterations in the immune response, cytokine secretion, environmental factors and the identification of new strategies to prevent end stage loss of islet function in patients with recent onset type 1 diabetes

Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	105	Scopus, Pubmed, Scholar, WoS	1986	2019
Papers [national]	3	Scopus	1989	2015
Book chapters	3	Scholar	1990	2010

Impact Factor	IF 2018 <i>InCites</i>	IF <i>in relazione all'anno di pubblicazione</i>
Total Impact factor	681.1	443.7
Average Impact Factor per Product	6.5	4.2
Citations	Scopus	Scholar
Total Citations	2856	4311
Average Citations per Product	27	41
Hirsch (H) index	29	35

Roma, 16.11.2019

Firma

